Anterior cruciate ligament (ACL) injuries requiring reconstruction are growing in frequency, with greater than 100,000 ACL reconstructions occurring annually in the United States.[@bib1] Health care systems, surgeons, and the wider community are more aware of the deleterious effects of prolonged and excessive opiate usage pre- and postoperatively, which has prompted a large body of research aimed at reducing the impact of this "epidemic."[@bib2], [@bib3], [@bib4], [@bib5] Opioid use has increased substantially in the past decade, due in part to emphasis on greater pain control in postsurgical patients, and prescribing practices vary widely in orthopaedic surgery, including after ACL procedures.[@bib6]^,^[@bib7] There is a delicate balance between providing adequate analgesia and overprescribing narcotics, especially in vulnerable patient populations, such as adolescents. Illicit diversion of these medications may be a substantial contributor to significant opioid-related abuse and opioid-related mortality.[@bib10], [@bib8], [@bib9] A recent study found that patients younger than 25 years of age were at an increased risk of filling opioid prescriptions postoperatively.[@bib11] It is also particularly important to consider this factor in relation to outpatient/day procedures, where pain management and recovery will be largely patient-driven. In the context of these issues, however, very little literature exists on specific numbers of pills or dosages taken after common knee surgical procedures, including ACL reconstruction or ACL repair. This information is crucial to help modify prescribing patterns and developing standardized guidelines to reduce opioid-associated morbidity.

In addition, with the introduction of surgical procedures, it is crucial to understand the impact these procedures have on postoperative pain to continue safe analgesic prescribing practices. The bridge-enhanced ACL repair technique has been shown to be a safe and effective alternative to anterior cruciate ligament reconstruction (ACLR) in a small group of patients.[@bib12] The purposes of this study were to compare postoperative pain scores and opioid usage between patients undergoing a standard arthroscopic ACL reconstruction using hamstring autograft (ACLR) with those undergoing a suture repair augmented with an extracellular matrix scaffold (bridge-enhanced ACL repair) performed through an arthrotomy and to determine factors predictive of postoperative opioid use and levels of overprescription. We hypothesized that there would be no increase in the postoperative opioid requirement for the subjects undergoing bridge-enhanced ACL repair when compared with ACLR.

Methods {#sec1}
=======

Trial Design {#sec1.1}
------------

An Investigational Device Exemption (IDE; G140151) from the Food and Drug Administration and an institutional review board approval from were obtained before initiating the study. The trial was registered on [ClinicalTrials.gov](http://ClinicalTrials.gov){#intref0010}. All patients granted their informed consent before participating. The study was designed under the guidance of the Food and Drug Administration as an interventional, parallel assignment, nonrandomized first-in-human trial for a specific extracellular matrix scaffold designated for use in a bridge-enhanced ACL repair. For all physical examination and functional testing, the examiner was blinded to the group assignment and operative knee. All surgeries were performed at a single site by a single surgeon. Ten patients were enrolled in the interventional (bridge-enhanced ACL repair) and 10 in the control (autograft hamstring ACLR) groups. No regional anesthesia was administered. Enrollment was completed from February to October of 2015, and the patient-reported outcomes and functional results have been previously reported.[@bib13]

### Participants and Entry Criteria {#sec1.1.1}

Patients aged 18 to 35 years with a complete, mid-substance ACL tear who were less than 1 month from injury and who had at least 50% of the length of the ACL attached to the tibia on their preoperative magnetic resonance imaging were eligible to enroll in the bridge-enhanced ACL repair group. As the ACL remnant is commonly removed during ACLR, and thus resorption of the torn ACL over time was not as critical, patients with a complete ACL tear who were within 3 months of injury were eligible to enroll in the ACLR group. Patients with a partial ACL tear were not eligible. Patients were excluded from either group if they had a history of previous surgery on the knee, history of previous infection in the knee, or had risk factors that might adversely affect healing. Patients were excluded if they had a displaced bucket handle tear of the medial meniscus that required repair; all other meniscal injuries were included. Patients were excluded if they had a full-thickness chondral injury, a grade III medial collateral ligament injury, a concurrent complete patellar dislocation, or an operative posterolateral corner injury. Patients in the bridge-enhanced ACL repair group also were excluded at the time of surgery if they were found to have less than 50% of the length of the ACL still attached to the tibial footprint.

Two hundred forty-two patients presenting with an ACL injury were screened for participation in this study. Of the 242 patients screened, 22 were enrolled in the study, of whom 2 were excluded before surgery, one due to a history of corticosteroid use not discovered in the initial enrollment meeting and the second patient elected to move to Florida for school. The primary reason for exclusion before enrollment was age (181 patients).

### Extracellular Matrix Scaffold {#sec1.1.2}

The extracellular matrix scaffold (BEAR Scaffold) passed all biocompatibility and sterility testing.[@bib14], [@bib15], [@bib16] The scaffold was composed of extracellular matrix proteins, including collagen, that were obtained from bovine tissue. The scaffold measured 22 mm in diameter by 45 mm in length and was hydrophilic; able to absorb up to 5 times its weight in fluid. The scaffold was conformable to the intra-articular notch and able to fill in the irregular contours of the gap between the torn ligament ends. The safety and efficacy of the scaffold for stimulating ACL healing have been reported in preclinical studies before beginning the trial[@bib17], [@bib18], [@bib19], [@bib20] and for this first-in-human trial.[@bib13]^,^[@bib21]

Surgical Techniques {#sec1.2}
-------------------

An examination under anesthesia was performed to verify that the ACL of the injured knee was deficient. A knee arthroscopy was performed and meniscal pathology addressed if necessary, and then a bridge-enhanced ACL repair was performed as previously described.[@bib12]^,^[@bib13] To summarize in brief, 4.5-mm tunnels were made in the femur and tibia. A 50-mm medial arthrotomy was made and a whip stitch of \#2 absorbable sutures (VICRYL; Ethicon, Somerville, NJ) was placed into the tibial stump of the torn ACL. Two \#2 non-absorbable sutures (ETHIBOND; Ethicon) were looped through the 2 center holes of a cortical button (ENDOBUTTON; Smith & Nephew, Andover, MA) and the free ends of the suture from the tibial stump passed through the cortical button. The button carrying the nonabsorbable and absorbable sutures was passed through the femoral tunnel and engaged on the lateral femoral cortex. The \#2 nonabsorbable sutures were passed through the scaffold and then brought through the tibial tunnel. Ten cc of autologous blood was obtained from the patient via venipuncture and added to the scaffold which was then passed up along the sutures into the femoral notch. The nonabsorbable sutures were tensioned with the knee in full extension and tied over a second cortical button on the anterior tibial cortex. The absorbable sutures from the tibial stump were tied over the femoral cortical button to bring the tibial ACL stump into the scaffold and directed towards the location of the femoral insertion. The arthrotomy was closed in layers.

### ACL Reconstruction With ACLR {#sec1.2.1}

A standard quadruple bundle hamstring autograft ACLR procedure was performed. The hamstrings were harvested through a small incision along the proximal medial tibia. A quadruple semitendinosus-gracilis graft was created and looped over a continuous-loop cortical button (ENDOBUTTON; Smith & Nephew) for proximal fixation. A bioabsorbable interference screw (BioRCI HA; Smith & Nephew) was used for tibial fixation through the hamstring harvest incision.

Postoperative Rehabilitation: Both Groups {#sec1.3}
-----------------------------------------

For all patients, a locking hinged brace (TScope; Breg, Carlsbad, CA) was applied to limit joint range of motion between 0 to 50° of knee flexion for the first 2 weeks postoperatively, from 0 to 90° for the next 4 weeks unless they had a concomitant meniscal repair, in which case the brace range was restricted to 0 to 40° for the first 4 weeks postoperatively before opening the brace up to 0 to 90° of flexion. All patients were provided with a cold therapy unit (Iceman; DJO Global, Vista, CA) for postoperative use. Both groups followed the same standardized physical therapy protocol with range of motion restricted from 0 to 90° for 6 weeks, partial weight bearing restricted for 2 weeks, then weight bearing as tolerated with crutches until 4 weeks postoperatively. Use of a functional ACL brace (CTi brace; OSSUR, Orange County, CA) was recommended from 6 to 12 weeks postoperatively.

Outcome Measures {#sec1.4}
----------------

Pain was assessed via a visual analog scale (VAS), along with simple functional outcomes including effusion and range of motion. Patient-reported outcome measures, including the International Knee Documentation Committee (IKDC) score and the Knee Injury and Osteoarthritis Outcome Scores (KOOS), were recorded at baseline and at each postoperative visit up to 2 years. The VAS is a unidimensional measure of pain intensity, consisting of a straight line 78 mm in length with endpoints defining opposing extremes of pain; "No pain" and "Worst pain." The subject is asked to mark his/her pain level representing the pain in their knee on that day, on the line between the endpoints. The distance between "No pain" and the subject's mark is then measured in mm and divided by the 78 mm total length to obtain the final VAS score (0 = no pain, 1 = worst pain). The IKDC Subjective Score and the KOOS score consisting of 5 components, including a Pain Score, were used to assess patient-reported outcomes.[@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27] A pain medication log was provided to subjects on discharge. Subjects were asked to document the time, date, medication, and dose for each medication used, which was then collected and reviewed at their 2-week postoperative appointment. Additional pain medications used in the postanesthesia care unit were recorded from the medical chart. No regional anesthesia was performed. Oxycodone discharge prescriptions also were collected from the medical chart. Overprescription of opioids was calculated by subtracting the total oxycodone taken after discharge (i.e., excluding any oral opioid given as an inpatient before discharge and any other oral opioids taken by the patient that were not prescribed) from the amount prescribed to the patient. The unused rate was calculated as the amount not taken as a percentage of that which was prescribed. No refill prescriptions were filled by any patient. Morphine-equivalent dose (MED) values were calculated using the Centers for Disease Control and Prevention conversion table[@bib28] based on all opiate medication taken postoperatively.

Statistical Analysis {#sec1.5}
--------------------

Subject characteristics at baseline and surgery are summarized with descriptive statistics. Differences between treatment groups were assessed using *t* test. Mixed effects models were used to assess the association of repeated measures of outcomes with treatment (treatment = bridge-enhanced ACL repair vs ACL reconstruction) over time. Models with treatment∗time interaction were fitted. If the interaction term was not statistically significant, models were fitted without it. As there was no significant effect of surgical group on the postoperative opioid use, the 2 groups were pooled to determine the effect of other variables. We assessed the univariate correlation of preoperative and intraoperative variables, including age, sex, body mass index (BMI), IKDC, KOOS, tourniquet time, and meniscus repair, with postoperative opioid use, measured as the total MED and dose per day. We then included the variables that showed statistically significant correlation with postoperative opioid use in regression models, adjusted for demographics. SAS. version 9.4 (SAS Institute, Cary, NC) was used for the analysis. Statistically significant results are noted if the *P* value is less than .05.

Results {#sec2}
=======

Baseline Characteristics and Intraoperative Findings {#sec2.1}
----------------------------------------------------

The baseline characteristics of both groups are shown in [Table 1](#tbl1){ref-type="table"} and have been previously published.[@bib12]^,^[@bib13] In summary, the 2 groups were similar in age, sex, race, and BMI. The average age of the bridge-enhanced ACL repair group was 24.1 ± 4.9 years and 24.6 ± 5.5 years in the ACLR group. The mean time from injury to surgery was significantly longer in the ACLR group (21 days vs 53 days). The numbers of patients with concomitant meniscal tears were similar between groups, as was the degree of effusion at the time of surgery.Table 1Baseline CharacteristicsCharacteristicBridge-Enhanced ACL Repair\
(N = 10)ACLR\
(N = 10)Demographics Male42 White, Non-Hispanic78 Age, y24.1 (±4.9)24.6 (±5.5) Range(18.1, 34.6)(18.6, 33.8) BMI24.2 (±2.0)25.1 (±2.9) Injury to surgery, d20.8 (±4.8)52.9 (±16.7)*P* \< .001 Range(11, 28)(24, 80) Meniscal tear 4 (1 or more)[∗](#tbl1fnlowast){ref-type="table-fn"}5 Effusion grade (0-3)[†](#tbl1fndagger){ref-type="table-fn"}1.3 (±0.7)0.9 (±0.8) Highest score22[^2][^3][^4][^5]

Pain Outcomes {#sec2.2}
-------------

No patient in either group required postoperative admission, readmission, or an emergency department visit for pain issues. VAS results at 2 weeks, 6 weeks, 3 months, 6 months, 1 year, and 2 years demonstrated no difference between the 2 groups; the values in both groups decreased over time at a similar rate (*P* value for treatment∗time interaction = .8512, *P* value for time \<.004), reaching a mean score at 2-years of .04 for both the bridge-enhanced ACL repair and ACLR groups. [Table 2](#tbl2){ref-type="table"} shows pain scores from baseline to 2 years in the 2 groups.Fig 1Correlation of preoperative KOOS Pain Score (A) and BMI (B) with postoperative opioid use. Note that a greater KOOS Pain Score is indicative of less pain reported. KOOS, Knee Injury and Osteoarthritis Outcome Scores; BMI, body mass index.Table 2Pain Scores for BEAR Versus ACLROutcomeBEAR (n = 10)ACLR (n = 10)*P* Value[∗](#tbl2fnlowast){ref-type="table-fn"}NMean (SD)NMean (SD)Visual analog scale 2 wk100.59 (0.28)100.72 (0.23).2835 6 wk100.27 (0.24)100.17 (0.16).2841 3 mo (12 wk)100.19 (0.15)100.14 (0.23).5472 6 mo (26 wk)100.20 (0.24)90.15 (0.16).5876 1 y (52 wk)100.11 (0.14)80.18 (0.27).4631 2 y (104 wk)80.04 (0.11)70.04 (0.08).9586[^6][^7]

Postoperative Opioid Consumption {#sec2.3}
--------------------------------

The total opiate intake measured as a MED ranged from 30 to 309 mg (4-42 pills of oxycodone) for the ACLR group and 75 to 254 mg (10-32 pills) for the bridge-enhanced ACL repair group in the first 2 weeks after surgery and was not significantly different between the 2 groups ([Table 3](#tbl3){ref-type="table"}, *P* = .18). Of this total, the amount taken as an outpatient for the ACLR group ranged from 22.5 to 277.5 mg (3-37 pills of oxycodone) and 75 to 253.5mg (10-34 pills) MED for the BEAR group ([Table 3](#tbl3){ref-type="table"}, *P* = .18). The average total MED consumed per day was 35.8 mg (5 pills) for the bridge-enhanced ACL repair group, and 44.2 mg (6 pills) for patients undergoing ACLR, which was not significantly different ([Table 3](#tbl3){ref-type="table"}, *P* = .29).Table 3Opioid Use for Bridge-Enhanced ACL Repair Versus ACLROutcomeBridge-Enhanced ACL Repair (n = 10)ACLR (n = 10)*P* ValueMean (SD)\
\[Range\]Mean (SD)\
\[Range\]Inpatient medications\>.70 Total MED administered in postanesthesia care unit18.0 (20.2)\
\[0-72\]15.3 (8.0)\
\[6-26.1\]Outpatient medications\>.48 Total MED of oxycodone, mg145.5 (69.0)\
\[0-232.5\]118.5 (96.6)\
\[0-277.5\] Total MED of all outpatient meds, mg[∗](#tbl3fnlowast){ref-type="table-fn"}169.2 (52.1)\
\[75-237\]123 (91.3)\
\[22.5-277.5\]\>.18 Total MED of all outpatient meds converted to number of 5 mg pills of oxycodone[∗](#tbl3fnlowast){ref-type="table-fn"}23\
\[10-32\]17\
\[3-37\]\>.18Total MED, inpatient and outpatient, mg187.2 (57.1)\
\[75-253.5\]138.3 (94.6)\
\[29.7-308.5\]\>.18 Total MED of all meds converted to number of 5 mg pills of oxycodone[∗](#tbl3fnlowast){ref-type="table-fn"}25\
\[10-34\]19\
\[4-42\]\>.18 Average MED per day, mg35.8 (12.8)\
\[15-53.6\]44.2 (20.9)\
\[14.4-71.1\]\>.29[^8][^9]

Predictors of Increased Opioid Use {#sec2.4}
----------------------------------

As there was no significant difference in either opioid consumption in total MED or MED per day, the 2 groups were combined in the univariate analysis for predictors. The univariate analysis revealed that greater preoperative BMI (*P* = .01) and lower (indicating more pain) preoperative KOOS Pain Score (*P* = .02) correlated with increased postoperative opioid use per day ([Fig 1](#fig1){ref-type="fig"}, [Table 4](#tbl4){ref-type="table"}), but no factor correlated with total MED postoperative dose. The associations with the per-day use remained statistically significant when both were included in a regression model adjusted for patient demographics. The addition of a meniscus tear requiring operative treatment at the time of ACL surgery did not impact postoperative opioid use, neither total amount or dose per day ([Fig 2](#fig2){ref-type="fig"}). The following were also not found to have an association with either measure of increased opioid consumption: age, sex, preoperative IKDC score, or total intraoperative tourniquet time.Table 4Correlation of Preoperative and Intraoperative Variables with Postoperative Opioid UseVariableMED per dayTotal MEDCorrelation Coefficient*P* ValueCorrelation Coefficient*P* ValueAge--0.3613.1176--0.1883.4267BMI**0.5934.0058**0.2386.3109Baseline IKDC--0.2037.3890--0.2259.3382Baseline KOOS Symptoms--0.0344.88550.1359.5677Baseline KOOS Pain--**0.5062.0228**--0.2236.3432Baseline KOOS ADLs--0.3542.1255--0.2379.3124Baseline KOOS Sports--0.2021.3930--0.2872.2195Baseline KOOS QOL--0.3305.1547--0.3829.0956Tourniquet Time, min--0.4184.0664--0.2797.2323[^10][^11]Fig 2Comparison of total MED (A) and opioid use per day (B) in patients with and without a meniscal repair. MED, morphine-equivalent dose.

Oversupply/Overprescription {#sec2.5}
---------------------------

Across both groups, the average amount prescribed was 63 pills of oxycodone (5 mg each). This led to an average prescribed oversupply of oxycodone of 43 pills per patient (amount remaining after ceasing use) with a range of oversupply from 23 pills to 74 pills ([Table 5](#tbl5){ref-type="table"}).Table 5Oxycodone Prescription Versus ConsumptionOutcomeBridge-Enhanced ACL Repair (n = 10)ACL Reconstruction (n = 9)*P* ValueMean (SD)Mean (SD)Total no. oxycodone pills prescribed64.8 (10.1)\
\[60-84\]60 (0)\
\[60-60\]\>.17Total no. oxycodone pills taken19.4 (9.2)\
\[0-31\]13.8 (11.9)\
\[0-37\]\>.27Total no. oxycodone pills left over45.4 (16.5)\
\[29-74\]46.2 (11.9)\
\[23-60\]\>.90[^12]

Discussion {#sec3}
==========

There was no difference in total opioid use between the 2 groups. This suggests that even though the bridge-enhanced ACL repair procedure requires an arthrotomy, this may not result in increased opioid use over the standard arthroscopic ACL reconstruction procedure. The potential postoperative pain from the arthrotomy in the bridge-enhanced ACL repair group may be mitigated by the lack of donor-site morbidity from a hamstring graft harvest site in these patients. This is important to patients and surgeons alike, particularly considering the increasing worries surrounding opioid diversion and unregulated use following surgical procedures.[@bib29]^,^[@bib30] Surgeons have become increasingly aware of opioid use in their patients, and the data presented here suggest no additional opioid use is needed with bridge-enhanced ACL repair (as opposed to ACL reconstruction). In addition, these data provide the first glimpse of opioid requirements for the postoperative outpatient phase of this procedure, even without the use of a nerve block, which may help contribute to standardized opioid prescribing practices for bridge-enhanced repair, as is currently being advocated for in other procedures.[@bib31]^,^[@bib32]

There is limited evidence in the previous literature detailing opioid consumption patterns in patients undergoing an ACL reconstruction or related procedure, likely largely due to its outpatient nature and subsequent difficulty with accurate follow-up. Tepolt et al.[@bib33] were able obtain a 60% follow-up rate when using patient-reported medication logbooks and found that for those undergoing any ACL procedure, the mean number of opioid pills (1 pill = 5 mg oxycodone = 7.5 mg MED) consumed was 20.6 ± 13.3 (range 0-69). This equates to a 155 ± 100mg MED, similar to the 187.2 mg MED seen in the subjects treated with bridge-enhanced ACL repair and the 138.3 mg MED seen in the subjects undergoing ACL reconstruction. Another study by Taylor et al.,[@bib34] which looked specifically at opioid consumption after ACLR, found a median use of 20 pills of oxycodone, equating to 150mg MED. MacDonald et al.[@bib35] compared groups undergoing single-bundle versus double-bundle ACLR and found an average oral opioid use of 39 and 49 pills in each group, respectively. However, in the study of MacDonald et al., there was no distinction made between an oral Percocet, oral Tramacet, or oral Tylenol-Codeine pill, so assuming each patient took only Tylenol-Codeine (which contains the least MED at 3 mg MED per pill), the average use was 117.6 mg MED for single bundle and 147 mg MED for double bundle ACLR. Although limited, this evidence is consistent with our small study. Of note, patients in our study were not given pre- or postoperative nerve blocks, which have been shown to reduce postoperative opioid use.[@bib36]^,^[@bib37]

Given the similarity between the 2 groups in terms of postoperative opioid use, we combined the 2 groups and then further analyzed both preoperative and intraoperative markers to predict postoperative opioid use in all patients. We demonstrated that patients with a greater BMI and those that had more pain in their injured knee preoperatively (indicated by a lower preoperative KOOS pain score) took more opioid medication postoperatively. This is consistent with Tepolt et al.,[@bib33] who showed via multivariate analysis that a patient's weight was predictive of postoperative opioid consumption. It has also been shown previously that filling opioid prescriptions preoperatively increased demand for postoperative opioid use after ACL reconstruction.[@bib11]^,^[@bib38] A related factor to this is preoperative pain and pain tolerance, in which we have demonstrated that those with a greater baseline preoperative pain took more opioids postoperatively. This may indicate the utility in obtaining preoperative pain scales in patients undergoing ACLR or a similar procedure to help adapt postoperative clinical care. This is an important clinical step in tailoring opioid prescription for patients known to have greater tendency to either require more opioid for better pain control, or to warrant more due to biological make-up. The ultimate aim is to reduce longer-term morbidity associated with excess use, and contribute to applicable opioid prescribing guidelines. In addition, we demonstrated that when meniscus repair is performed concurrently with an ACL reconstruction or bridge-enhanced ACL repair, there was no impact on postoperative opioid use. Beck et al.[@bib39] showed a similar finding in which the addition of meniscus repair or partial meniscectomy did not affect postoperative opioid use. Patients were excluded from our study if they had a displaced bucket-handle tear of the medial meniscus, so this particular type of meniscus injury cannot be commented on. With consideration of this limitation, it would seem that the ACL reconstruction/repair may be the primary factor dictating the pain response and subsequent opioid use in these patients.

Our study adds to the previous literature in regards to the overprescription of opioid medication in postsurgical orthopaedic patients, even in the setting of no pre- or postoperative nerve block. We demonstrated a greater than 70% unused opiate rate across the 20 patients enrolled into this clinical trial, equating to an average oversupply of 46 pills of oxycodone. This was consistent with a recently published study that reported a 68% unused opioid rate in adolescents and young adults undergoing knee arthroscopy and related procedures.[@bib33] Kim et al.[@bib40] evaluated opioid use after upper-extremity surgical procedures and found a 66% unused rate. Sabatino et al.[@bib6] looked at adult patients undergoing 5 common elective orthopedic procedures (total hip arthroplasty, total knee arthroplasty, endoscopic carpal tunnel release, arthroscopic rotator cuff repair and lumbar decompression) and demonstrated that 61% of patients had excess opioid medication remaining, accounting to 43,216 unused pills. These significant incongruence rates between opioids prescribed and opioids consumed for common orthopaedic procedures opens an opportunity for clinicians to begin to contribute to the reduction of opioids in the community. This would be a positive step in restricting potential for illicit diversion of these medications, which is aggravated by the lack of knowledge about safe disposal practice, which has previously been reported.[@bib6]^,^[@bib33]^,^[@bib39]^,^[@bib41]

The current analysis directs the need for further research on pain outcomes and medication use following the bridge-enhanced ACL repair technique. It would further be of use to look at opioid use in conjunction with the commonly used femoral nerve or adductor canal block in patients undergoing the bridge-enhanced ACL repair procedure, to see if corresponding reductions in opioid use are seen. Our study continues to add evidence for the substantial over prescription of opioids to both adolescents and adults for postoperative pain after orthopaedic procedures. We have subsequently made systematic changes to our prescribing practices at our institution and encourage others to follow.

Limitations {#sec3.1}
-----------

There are several limitations of our current study. It was constructed primarily for the analysis of safety outcomes, and only enrolled small numbers. Thus, we acknowledge the possibility that this study is underpowered, with only 10 subjects in each treatment group. A priori power calculation was not performed based on opioid consumption because it is not the primary outcome as planned. The trial and sample size calculation were designed to report adverse events and ensure safety. However, ad hoc power analysis applied to studies with negative findings is unreliable because the calculation of power based on observed negative results will always lead to low power.[@bib42]^,^[@bib43] Further, attributing the negative results to low power is problematic. Instead, as recommended by current literature,[@bib42]^,^[@bib43] we examined the confidence intervals (95% CI) of our estimates. For average opioid use per day, the mean difference between groups (ACLR -- BEAR) is 8.3 mg (1.1 pills) (95% CI --7.9 to 24.6, *P* = .30). First, this means we should not rule out the possibility that there is no difference between groups because zero in contained in the 95% CI. Second, it is possible that the daily opioid use in the ACLR group is 7.9 mg (1.1 pills) lower than the BEAR group. Conversely, the data are also consistent with the possibility that daily use is 24.6 mg greater in ACLR than BEAR. This translates into patients undergoing ACLR taking 3.3 more pills per day than patients undergoing BEAR. A similar argument can be made for total MED, for which the mean difference is --48.8 mg (6.5 pills) (95% CI --122.2 to 24.6, *P* = .18). Therefore, we concluded that opiate intake is likely not different between groups. Detailed postoperative opioid consumption in terms of actual pills consumed following outpatient orthopaedic procedures is also scarce in the literature and so even small numbers adds weight to current knowledge, especially in a younger population. Quantities of opioid consumption were also patient reported and therefore it is important to acknowledge that this could lead to an underestimate of intake in patients who may not have accurately completed their medication logs. However, all patients completed their logs and provided evidence of this, removing the issue of selection bias. Finally, all patients were operated on by a single surgeon at a single institution, which may reduce variability, but may also make our conclusions less generalizable.

Conclusions {#sec4}
===========

Total overall opiate intake was not different between the patients undergoing BEAR through an arthrotomy and those undergoing arthroscopic ACLR. Both groups had similar pain scores from 2 weeks to 2 years postoperatively. Greater BMI and greater preoperative pain (lower KOOS pain score) correlated with greater postoperative opioid use per day. There was an overprescription of opioids across all patients.

Supplementary Data {#appsec1}
==================
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[^1]: The BEAR Trial Team: Rachael Henderson, Christina Freiberger, Bethany Trainor, Benedikt Proffen, Dennis Kramer, Yi-Meng Yen.

[^2]: NOTE. Data presented as mean (±standard deviation). Previously published with the 3-month and 2-year data for this group.[@bib12]^,^[@bib13]

[^3]: ACL, anterior cruciate ligament; ACLR, anterior cruciate ligament reconstruction.

[^4]: Bridge-enhanced ACL repair: 1 lateral tear in 1 patient, 2 lateral tears in 1 patient , 1 medial tear in 2 patients. ACLR: 1 lateral tear in 3 patients, 2 lateral tears in 1 patient, 1 medial tear in 1 patient.

[^5]: N = 9 in the ACLR group.

[^6]: ACL, anterior cruciate ligament; ACLR, anterior cruciate ligament reconstruction; BEAR, bridge-enhanced ACL repair; SD, standard deviation.

[^7]: *P* value for *t* test, Satterthwaite *P* if unequal variance.

[^8]: CL, anterior cruciate ligament; ACLR, anterior cruciate ligament reconstruction; BEAR, bridge-enhanced ACL repair; MED, morphine-equivalent dose; SD, standard deviation.

[^9]: Includes all outpatient opioids consumed (as documented on patient pain medication log), including those not prescribed directly by our institution.

[^10]: NOTE. Boldface indicates statistical significance.

[^11]: ADL, activity of daily living; BMI, body mass index; IKDC, International Knee Documentation Committee; KOOS, Knee Injury and Osteoarthritis Outcome Scores; MED, morphine-equivalent dose; QOL, quality of life.

[^12]: ACL, anterior cruciate ligament; SD, standard deviation.
